Thursday, March 19, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with TameraLynn Stewart, patient advocate turned lawmaker

We interview TameraLynn Stewart, one of the most successful chronic pain advocates in the country, who turned her experiences with pain and cancer into public health advocacy. She was one of many advocates who authored Senate Bill 57 (SB57), which proved to be landmark legislation, making Oklahoma one of the first states to reverse course on poorly conceived opioid policies – turning against restrictive prescribing practices and towards patient centric opioid policies.

To learn more about her law, SB57, please select the link below:

https://openstates.org/ok/bills/2021/SB57/

To learn more about her advocacy, please select the link below:

https://painadvocate.org/

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!